Cell Therapy Funding Tracker (188 deals)

Our funding tracker covering the cell therapy market

Below is the table listing all the deals. You may find our methodology at the end of this page.

And, if you want to gain a deeper understanding of the market and its current dynamics, get our report covering the Cell Therapy Market.

Is cell therapy actually a well-funded market right now?

Cell therapy is well funded today, but most companies are raising nothing like the giant rounds that dominate the headlines.

We tracked 185 qualifying financings across 151 companies, representing at least $4.20 billion of measurable private capital. The typical round is much smaller than that total might suggest: the median numerical financing is $14 million, compared with a $27.1 million average.

The gap comes from the top of the market. Only 20 financings exceeded $50 million, yet they generated 55.5% of measured capital. Once those rounds are removed, funding falls to roughly $1.87 billion.

There is also some unavoidable uncertainty around the total. Thirty deals do not have a reliable numerical amount, while another 18 are disclosed only as lower bounds. We are much more confident about the shape of the market than about pretending every invested dollar can be counted exactly.

Market metric	Result
Qualifying financings	185
Funded companies	151
Measured capital	≥$4.20B
Capital excluding >$50M rounds	≈$1.87B
Median numerical round	$14.0M
Average numerical round	$27.1M
>$50M financings	20
Capital from >$50M financings	55.5%

How many cell therapy companies are actually getting funded?

We count 151 funded cell therapy companies behind the 185 financing events.

Most only appear once. There are 127 companies with one financing during the period, 16 with two and eight with at least three. In total, just 24 companies come back for another round inside the window.

That is a useful reality check when reading funding news. A stream of financing announcements can make the market feel as if hundreds of different startups are raising money, when some companies are returning to investors more than once.

Repeat fundraising still does not dominate the capital. Companies that appear once account for about $2.87 billion, compared with roughly $1.33 billion for repeat fundraisers. So there really is a broad company base here; the deal count simply makes it look a little larger than it is.

Is cell therapy funding concentrated in a handful of companies?

Yes. The ten best-funded cell therapy companies capture 40.6% of measured capital, although the money is spread across several large winners rather than one dominant company.

ArsenalBio is the largest at $325 million during the period, equal to about 7.7% of measured funding. The top five companies reach 27.0%, while the top ten reach 40.6%.

That concentration becomes more interesting further down the market. Only about 13.9% of companies exceed $50 million in cumulative funding during the window. At the other end, more than a quarter of companies whose funding can be measured confidently never get beyond $5 million.

The company base is fairly wide. The group able to access serious scale capital is much narrower.

Company	Capital raised in the window	Financings
ArsenalBio	$325M	1
OriCell Therapeutics	$280M	2
Neurona Therapeutics	$222M	2
Obsidian Therapeutics	$160.5M	1
Outpace Bio	$144M	1
BrainChild Bio	$116M	1
Aspect Biosystems	$115M	1
Aspen Neuroscience	$115M	1
Wugen	$115M	1
AvenCell Therapeutics	$112M	1

What does a normal cell therapy funding round actually look like?

For a typical cell therapy company, a realistic financing is around $14 million, far below the $50 million to $300 million rounds that get most of the attention.

More than half of the financings with known amounts are below $20 million. Another 45 sit between $20 million and $50 million. Large rounds are uncommon enough that only 22 known financings reach $50 million or more.

The dollars tell a very different story. The 88 financings below $20 million contribute roughly $625 million combined. The 13 rounds of at least $100 million contribute about $1.83 billion.

So when somebody says that cell therapy attracts enormous amounts of capital, both things can be true at once: the overall market is large, while the ordinary company is still raising a relatively normal biotech-sized round.

Deal size	Deals	Share of deals	Measured capital
<$5M	42	22.7%	$102.2M
$5M–<$20M	46	24.9%	$523.3M
$20M–<$50M	45	24.3%	$1.14B
$50M–<$100M	9	4.9%	$594.7M
$100M+	13	7.0%	$1.83B
Amount not measurable	30	16.2%	—
Total	185	100%	≥$4.20B

Which type of cell therapy is getting the biggest checks?

CAR-T is where the biggest cell therapy checks are going today.

We count 39 CAR-T financings worth roughly $1.69 billion. That is only about one-fifth of all deals but 40.2% of measured capital.

Regenerative cell therapies are actually more common, with 63 financings, yet they account for about $1.05 billion. Engineered immune cells follow at $724.9 million, allogeneic therapies at $465.1 million and autologous therapies at $275.1 million.

The difference becomes fairly obvious when we look at the companies behind those numbers. CAR-T has several businesses reaching expensive clinical programs at the same time. Regenerative therapy has a broader mix of early platforms, development-stage programs and later clinical companies, so its typical check stays smaller.

Autologous cell therapy is particularly sensitive to individual deals. Aspen Neuroscience alone represents around 42% of the category's measured funding. One large financing changes the appearance of that segment quite dramatically.

Why are CAR-T companies raising so much more money?

CAR-T companies start needing very large amounts of money once they move from platform work into clinical trials, manufacturing and regulatory execution.

ArsenalBio's $325 million Series C is the clearest example. The company said the financing would advance its programmable CAR-T programs through clinical development. OriCell also raised at a very different scale from most of the market as it pushed solid-tumor CAR-T programs globally.

Obsidian Therapeutics shows the same spending pattern in engineered immune cells. Its $160.5 million Series C was raised to support ongoing multicenter clinical development of OBX-115. These companies are running clinical programs while trying to build repeatable manufacturing processes around living products. That gets expensive fast.

The regulatory work is substantial too. FDA's CAR-T guidance covers CMC, pharmacology and toxicology, and clinical-study design. More recently, FDA has published additional guidance giving cell and gene therapy developers more flexibility around some CMC requirements. That can make development more practical, but manufacturing is hardly becoming cheap or simple.

Lately, ArsenalBio has also shifted its focus toward in vivo CAR-T and reduced its workforce. A $325 million historical round should be read in that context: investors were financing a technically ambitious clinical strategy, not certainty that the original approach would work exactly as planned.

Are regenerative cell therapies getting left behind?

Regenerative cell therapy is getting plenty of funding, but its money is spread across many more small and mid-sized rounds than CAR-T.

The category has the highest deal count in our research, with 63 financings across 46 companies. Measured capital reaches roughly $1.05 billion, and the median round is $12.5 million.

Neurona Therapeutics shows what happens once one of these companies moves further into the clinic. It raised $120 million after early clinical progress, then another $102 million as NRTX-1001 moved toward a Phase 3 epilepsy study intended to support a future biologics application.

Regenerative cell therapy can clearly produce nine-figure financings. There are simply many earlier companies sitting underneath those larger clinical-stage deals, which pulls down the typical check.

Is cell therapy funding creating lots of new startups?

Cell therapy funding today mostly keeps existing venture-backed companies moving rather than creating a fresh wave of new ones.

We classify 155 financings as follow-ons, equal to 83.8% of the market. Only 28 are first external financings, while two could not be classified reliably.

First rounds are smaller too. Their median is $9.6 million, compared with $15 million for follow-on financings.

The founding years point in the same direction. The biggest company cohorts were created between 2018 and 2022, and only seven funded companies in our research were founded in 2024 or 2025.

These days, most cell therapy dollars are following companies that already have several years of scientific and organizational work behind them. New companies are still getting started, but they are not driving the market.

How old are cell therapy companies before investors write really big checks?

Big cell therapy checks usually arrive after several years of company-building: the median funded company is five years old, while companies raising more than $50 million have a median age of roughly seven years.

The stage progression is remarkably clean. Companies are around three years old at Seed, five at Series A, seven at Series B, eight at Series C and 12 at Series D+.

Companies raising less than $5 million are much younger, at roughly 4.5 years at the median.

This makes intuitive sense for cell therapy. Investors can fund an early scientific idea quickly, but getting into the large-check market usually requires more evidence: a developed platform, preclinical work, manufacturing progress, regulatory interaction or actual patient data.

The biggest rounds therefore tend to look less like classic startup funding and more like financing a multi-year drug-development program.

How much can a cell therapy startup raise at each stage?

A cell therapy startup typically moves from about $2.6 million at Seed to $15 million at Series A, $23.4 million at Series B and $29.4 million at Series C.

The increase is real, but it is not a smooth staircase where every later round is automatically huge. There is enormous variation inside each stage, especially because financing labels do not always match the actual maturity of the company.

BrainChild Bio is one of the freshest examples. The company closed a $116 million Series A shortly before our cutoff, but the money is supporting a pivotal Phase 2 study of a CAR-T therapy for pediatric brain cancer. Calling that simply a "Series A startup" would give completely the wrong impression of what investors are financing.

That is why we use stage together with company age, clinical progress and use of funds rather than reading the round label on its own.

Stage	Deals	Median round	Measured capital
Seed	42	$2.62M	$191.3M
Series A	54	$15.0M	$1.12B
Series B	28	$23.4M	$721.3M
Series C	22	$29.4M	$1.25B
Series D+	5	$63.5M	$249.4M
Growth Equity	3	$20.2M	$242.7M
Unknown	31	$10.0M	$416.5M

Where does cell therapy funding get hardest to raise?

The first big cell therapy funding squeeze comes after Series A, and the private ladder gets extremely thin again after Series C.

We count 54 Series A financings and only 28 Series B rounds. The drop from B to C is smaller, from 28 to 22, before the count falls to just five conventional Series D+ financings.

Those numbers should not be read as literal survival rates. We are looking at all financings inside one fixed period rather than following the same companies from Seed to exit. Some businesses get acquired, go public, use pre-IPO structures or simply raise outside the window.

Still, the shape is hard to ignore. There is plenty of money for promising early companies and plenty for a small number of advanced clinical programs. The middle is where competition becomes much tougher, and by the time companies reach later private stages, the investor pool looks very narrow.

Where is cell therapy money actually going: the US, China or Europe?

North America gets the biggest cell therapy checks, China produces the most deals, and Europe remains a much smaller private-capital market.

North America accounts for 57 financings and approximately $2.35 billion, or 56.1% of measured capital. The United States alone contributes around $2.20 billion.

Asia-Pacific produces 101 financings, far more than North America, but about $1.64 billion of capital. China is doing most of that work: 75 deals across 52 companies and roughly $1.47 billion.

China therefore looks much more active than its capital share alone would suggest. OriCell's large rounds also show that the country is perfectly capable of producing major financings; it simply has a much larger population of smaller deals underneath them.

Europe looks very different. We count 25 financings across 24 companies, with a median round of only $3.9 million and roughly $201 million in total measured funding. We do not observe a single European financing above $50 million in the adjusted dataset.

For now, the regional gap looks less like a shortage of European cell therapy companies and more like a shortage of very large private checks.

Which investors keep leading cell therapy rounds?

Cell therapy lead investing is unusually diffuse: only ten disclosed lead investors appear more than once.

That is a little surprising because this looks, at first glance, like the kind of specialist market where a small circle of funds might repeatedly underwrite the same companies.

Instead, the most active names only lead or co-lead three financings each. Cormorant Asset Management, Qiming Venture Partners, Beijing Medical and Health Care Industry Investment Fund, ARCH Venture Partners and The Column Group sit at that level.

Fidelity Management & Research, Viking Global Investors, RA Capital Management, Apricot Capital and UTEC each recur twice.

Altogether, recurring lead investors touch only about 16% of financings where a lead is disclosed. The market depends on a wide mix of biotech specialists, growth investors, regional funds and larger institutional investors rather than a handful of permanent gatekeepers.

There is some caution around this result because lead-investor disclosure is available for only 118 of the 185 financings. Still, the visible part of the market is clearly broad.

Do pharma and other strategic investors really matter in cell therapy?

Strategic investors matter in cell therapy because the rounds they join are almost twice as large at the median.

We identify strategic participation in 46 financings, or roughly one quarter of the market. Those rounds have a $23.4 million median size, compared with $12.5 million when no strategic investor is disclosed.

Bristol Myers Squibb appears six times, more than any other strategic investor in our research. That involvement is not purely financial. Bristol Myers Squibb has had multi-program cell-therapy relationships with companies including ArsenalBio and Obsidian Therapeutics, giving it a reason to invest around technologies it is already following closely.

Takeda Ventures, Kyowa Kirin, NYBC Ventures, NATCO Pharma and Tasly Capital also recur.

Corporate money is not underwriting most cell therapy companies today. But strategic participation tends to show up around larger, more developed financings where the technology, clinical progress or an existing partnership has become interesting to an industry buyer.

Is cell therapy funding steady, or does it come in bursts?

Cell therapy deal flow is fairly steady, while monthly dollars still jump sharply whenever one clinical-stage company lands a huge round.

Across completed months, we find an average of 5.7 financings and a median of six. The busiest month produced 12, so deal activity never explodes to five or ten times its normal level.

Capital is much more erratic. The median completed month contains about $108.8 million of measurable funding, while the peak reaches roughly $437.3 million.

A $150 million or $300 million round can therefore transform the apparent size of one month without meaning that dozens more companies suddenly found investors.

The recent end of our window still shows that large checks are available. BrainChild Bio's $116 million financing came very close to the cutoff, while the broader market continues to produce small and mid-sized rounds alongside these occasional nine-figure deals.

As of now, cell therapy financing looks active rather than euphoric: companies keep getting funded, but the huge dollar totals still depend on a relatively small number of advanced programs.

What should we actually take away from the cell therapy funding data?

Cell therapy is a real multibillion-dollar private funding market, but the ordinary financing is much smaller than the biggest announcements suggest. Around $10 million to $30 million is far more representative of the market's middle than a nine-figure round.

There are roughly 150 funded companies in the period we studied, and most of them only raise once inside the window. Serious concentration appears at the top, but several companies share that capital rather than one business swallowing the market.

Investors are mostly backing companies that have already been around for years. Follow-on funding dominates, large checks tend to arrive later in a company's development and relatively few newly created businesses make up the funded population.

CAR-T currently stands apart because clinical-stage companies can absorb huge amounts of capital. The latest developments also show that the technology itself is still moving: in vivo CAR-T is getting more attention, FDA is continuing to refine the regulatory framework, and companies are still changing development strategies after raising very large sums.

The biggest weakness is the financing ladder. Getting through Series A is only the start. Series B activity falls sharply, and conventional later private rounds become rare after Series C. Cell therapy has plenty of capital, but access to it gets much more selective as companies move toward the expensive part of clinical development.